Program in Microbiology, Yale School of Medicine, New Haven, CT 06520, USA.
Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA.
Cell Host Microbe. 2019 Feb 13;25(2):219-232. doi: 10.1016/j.chom.2019.01.014.
Phage therapy, long overshadowed by chemical antibiotics, is garnering renewed interest in Western medicine. This stems from the rise in frequency of multi-drug-resistant bacterial infections in humans. There also have been recent case reports of phage therapy demonstrating clinical utility in resolving these otherwise intractable infections. Nevertheless, bacteria can readily evolve phage resistance too, making it crucial for modern phage therapy to develop strategies to capitalize on this inevitability. Here, we review the history of phage therapy research. We compare and contrast phage therapy and chemical antibiotics, highlighting their potential synergies when used in combination. We also examine the use of animal models, case studies, and results from clinical trials. Throughout, we explore how the modern scientific community works to improve the reliability and success of phage therapy in the clinic and discuss how to properly evaluate the potential for phage therapy to combat antibiotic-resistant bacteria.
噬菌体疗法长期以来一直被化学抗生素所掩盖,在西方医学中重新引起了人们的兴趣。这源于人类中多重耐药性细菌感染的频率增加。最近也有噬菌体疗法的病例报告表明,它在解决这些棘手的感染方面具有临床实用性。然而,细菌也可以轻易地产生噬菌体耐药性,因此现代噬菌体疗法必须制定策略来利用这种必然性。在这里,我们回顾了噬菌体疗法研究的历史。我们比较和对比了噬菌体疗法和化学抗生素,强调了它们在联合使用时的潜在协同作用。我们还研究了动物模型、病例研究和临床试验的结果。在整个过程中,我们探讨了现代科学界如何努力提高噬菌体疗法在临床上的可靠性和成功率,并讨论了如何正确评估噬菌体疗法对抗抗生素耐药菌的潜力。